Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
batzelladine P
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Batzelladine P is a guanidine alkaloid isolated from the deep-water marine sponge *Monanchora pulchra*. It exhibits cytotoxic activity against human prostate cancer cells, including docetaxel-resistant strains (PC3-DR). The compound induces apoptosis, as indicated by the cleavage of caspase-3 and PARP, and triggers pro-survival autophagy through the suppression of the mTOR pathway and upregulation of LC3B-II. Research indicates that combining batzelladine P with autophagy inhibitors synergistically increases its cytotoxic activity, making it a potential candidate for the treatment of taxane-resistant prostate cancer.
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)CASP3 (Caspase-3)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on batzelladine P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on batzelladine P.